在急性心力衰竭中Galectin-3的临床研究进展

Clinic reserch development of Galectin-3 in acute heart failure

急性心力衰竭作为全球性的问题,目前仍有较大的发病率及死亡风险。很多有研究证据表明,心力衰竭患者的Galectin-3浓度是评价其预后的独立危险因素,2013年的美国心力衰竭管理指南(ACCF/AHA)也提出,Galectin-3不仅能够预测心力衰竭患者住院及死亡风险,而且与利钠肽相关生物学指标联合使用可增加其评价预后的价值。本文简要综述Galectin-3作为新兴的生物学标志物其在急性心力衰竭的临床诊断和评估预后方面和的临床研究进展。

Acute heart failure(AHF)is still a global burden which carries substantial risk of morbidity and mortality.Numerous studies have shown galectin-3 as a prognostic biomarker with independent predictive value for cardiovascular mortality in HF patients.American heart failure management guidelines(ACCF/AHA)in 2013 also proposed that galectin-3 is not only predictive of hospitalization and death in patients with HF but also additive to natriuretic peptide levels in their prognostic value.In this paper,we will review the emerging biomarker-galectin-3 for the the clinical diagnosis,prognosis of acute heart failure.